Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle T Martin

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Public Health Reports (Washington, D.C. : 1974)|June 8, 2022
Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment AccessMichelle T Martin, Nicole Waring, Jasmine Forrest, et al.
Open Forum Infectious Diseases|August 1, 2019
Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven ModelDavid E Koren, Autumn Zuckerman, Robyn Teply, et al.
Pharmacoeconomics|May 28, 2025
Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database AnalysisMichelle T Martin, Krithika Rajagopalan, Dilip Makhija, et al.
Frontiers in Pharmacology|December 28, 2020
Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral TherapyNadia A Nabulsi, Michelle T Martin, Lisa K Sharp, et al.
International Journal of Clinical Pharmacy|November 10, 2020
Practical considerations when treating chronic hepatitis E in solid organ transplant recipientsDavid K Choi, Michelle T Martin, Wadih Chacra, et al.
BMC Health Services Research|October 30, 2024
Cost-effectiveness analysis of emergency department-based hepatitis C screening and linkage-to-care programSun A Choi, Kandavadivu Umashankar, Anjana Maheswaran, et al.
Journal of Public Health (Oxford, England)|February 4, 2021
Factors predicting staging and treatment initiation for patients with chronic hepatitis C infection: insurance a key predictorJanet Lin, Cammeo Mauntel-Medici, Anjana Bairavi Maheswaran, et al.
Pharmacotherapy|February 6, 2016
Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases PharmacistsPaulina Deming, Michelle T Martin, Juliana Chan, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Public Health Reports (Washington, D.C. : 1974)|June 8, 2022
Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment AccessMichelle T Martin, Nicole Waring, Jasmine Forrest, et al.
Open Forum Infectious Diseases|August 1, 2019
Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven ModelDavid E Koren, Autumn Zuckerman, Robyn Teply, et al.
Pharmacoeconomics|May 28, 2025
Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database AnalysisMichelle T Martin, Krithika Rajagopalan, Dilip Makhija, et al.
Frontiers in Pharmacology|December 28, 2020
Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral TherapyNadia A Nabulsi, Michelle T Martin, Lisa K Sharp, et al.
International Journal of Clinical Pharmacy|November 10, 2020
Practical considerations when treating chronic hepatitis E in solid organ transplant recipientsDavid K Choi, Michelle T Martin, Wadih Chacra, et al.
BMC Health Services Research|October 30, 2024
Cost-effectiveness analysis of emergency department-based hepatitis C screening and linkage-to-care programSun A Choi, Kandavadivu Umashankar, Anjana Maheswaran, et al.
Journal of Public Health (Oxford, England)|February 4, 2021
Factors predicting staging and treatment initiation for patients with chronic hepatitis C infection: insurance a key predictorJanet Lin, Cammeo Mauntel-Medici, Anjana Bairavi Maheswaran, et al.
Pharmacotherapy|February 6, 2016
Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases PharmacistsPaulina Deming, Michelle T Martin, Juliana Chan, et al.
Pageof 3